Riviere I - Search Results

1

Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy.

Smith M, Dai A, Ghilardi G, Amelsberg KV, Devlin SM, Pajarillo R, Slingerland JB, Beghi S, Herrera PS, Giardina P, Clurman A, Dwomoh E, Armijo G, Gomes ALC, Littmann ER, Schluter J, Fontana E, Taur Y, Park JH, Palomba ML, Halton E, Ruiz J, Jain T, Pennisi M, Afuye AO, Perales MA, Freyer CW, Garfall A, Gier S, Nasta S, Landsburg D, Gerson J, Svoboda J, Cross J, Chong EA, Giralt S, Gill SI, Riviere I, Porter DL, Schuster SJ, Sadelain M, Frey N, Brentjens RJ, June CH, Pamer EG, Peled JU, Facciabene A, van den Brink MRM, Ruella M. Smith M, et al. Among authors: riviere i. Nat Med. 2022 Apr;28(4):713-723. doi: 10.1038/s41591-022-01702-9. Epub 2022 Mar 14. Nat Med. 2022. PMID: 35288695 Free PMC article.

2

Retroviral-mediated gene transfer in primary murine and human T-lymphocytes.

Rivière I, Gallardo HF, Hagani AB, Sadelain M. Rivière I, et al. Mol Biotechnol. 2000 Jun;15(2):133-42. doi: 10.1385/MB:15:2:133. Mol Biotechnol. 2000. PMID: 10949826

3

Issues in the manufacture and transplantation of genetically modified hematopoietic stem cells.

Sadelain M, Frassoni F, Rivière I. Sadelain M, et al. Among authors: riviere i. Curr Opin Hematol. 2000 Nov;7(6):364-77. doi: 10.1097/00062752-200011000-00008. Curr Opin Hematol. 2000. PMID: 11055510 Review.

4

Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta /CD28 receptor.

Maher J, Brentjens RJ, Gunset G, Rivière I, Sadelain M. Maher J, et al. Among authors: riviere i. Nat Biotechnol. 2002 Jan;20(1):70-5. doi: 10.1038/nbt0102-70. Nat Biotechnol. 2002. PMID: 11753365

5

Sturm und drang over suicidal lymphocytes.

Sadelain M, Rivière I. Sadelain M, et al. Among authors: riviere i. Mol Ther. 2002 Jun;5(6):655-7. doi: 10.1006/mthe.2002.0619. Mol Ther. 2002. PMID: 12027547 Free article. Review. No abstract available.

6

A novel murine model of Cooley anemia and its rescue by lentiviral-mediated human beta-globin gene transfer.

Rivella S, May C, Chadburn A, Rivière I, Sadelain M. Rivella S, et al. Among authors: riviere i. Blood. 2003 Apr 15;101(8):2932-9. doi: 10.1182/blood-2002-10-3305. Epub 2002 Dec 12. Blood. 2003. PMID: 12480689 Free article.

7

Targeting tumours with genetically enhanced T lymphocytes.

Sadelain M, Rivière I, Brentjens R. Sadelain M, et al. Among authors: riviere i. Nat Rev Cancer. 2003 Jan;3(1):35-45. doi: 10.1038/nrc971. Nat Rev Cancer. 2003. PMID: 12509765 Review.

8

Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15.

Brentjens RJ, Latouche JB, Santos E, Marti F, Gong MC, Lyddane C, King PD, Larson S, Weiss M, Rivière I, Sadelain M. Brentjens RJ, et al. Among authors: riviere i. Nat Med. 2003 Mar;9(3):279-86. doi: 10.1038/nm827. Epub 2003 Feb 10. Nat Med. 2003. PMID: 12579196

9

The ABCs of artificial antigen presentation.

Kim JV, Latouche JB, Rivière I, Sadelain M. Kim JV, et al. Among authors: riviere i. Nat Biotechnol. 2004 Apr;22(4):403-10. doi: 10.1038/nbt955. Nat Biotechnol. 2004. PMID: 15060556 Review.

10

Novel strategies for cancer therapy: the potential of genetically modified T lymphocytes.

Rivière I, Sadelain M, Brentjens RJ. Rivière I, et al. Curr Hematol Rep. 2004 Jul;3(4):290-7. Curr Hematol Rep. 2004. PMID: 15217559 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

113 results

Search Page